PVG Asset Management Corp Has $1.34 Million Holdings in GRAIL, Inc. $GRAL

PVG Asset Management Corp grew its holdings in GRAIL, Inc. (NASDAQ:GRAL) by 167.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,907 shares of the company’s stock after acquiring an additional 16,234 shares during the quarter. PVG Asset Management Corp’s holdings in GRAIL were worth $1,339,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Royal Bank of Canada raised its stake in GRAIL by 17.7% during the 1st quarter. Royal Bank of Canada now owns 88,082 shares of the company’s stock valued at $2,250,000 after purchasing an additional 13,264 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in GRAIL by 28.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after purchasing an additional 623 shares during the last quarter. NewEdge Advisors LLC increased its holdings in shares of GRAIL by 390.3% during the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock worth $45,000 after purchasing an additional 1,401 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of GRAIL by 37.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company’s stock worth $2,362,000 after purchasing an additional 25,177 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of GRAIL by 115.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 79,544 shares of the company’s stock worth $4,090,000 after purchasing an additional 42,675 shares during the period.

Key Stories Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: GRAIL will present at the Canaccord Genuity 46th Annual Growth Conference on August 11. Management’s appearance could provide updates on commercial execution, adoption of its Galleri cancer-detection test and future growth plans. GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference
• Neutral Sentiment: GRAIL is expected to report its next quarterly results on Wednesday. The report may become the next major catalyst, particularly given the company’s continued losses and the market’s focus on revenue growth, cash usage and guidance. GRAIL Expected to Post Earnings on Wednesday
• Negative Sentiment: Multiple law firms publicized or reiterated a securities class action against GRAIL and certain executives, covering investors who purchased shares between May 13, 2025, and February 19, 2026. The firms allege federal securities-law violations connected with investor losses and are soliciting lead-plaintiff applicants.
• Negative Sentiment: The August 4, 2026 lead-plaintiff deadline is generating repeated investor alerts from Rosen, Hagens Berman, Robbins Geller, Bleichmar Fonti & Auld, and other firms. Although the allegations have not been proven, the concentration of notices can increase uncertainty around potential damages, legal expenses and management attention. Rosen Law Firm GRAIL Investor Deadline Notice

GRAIL Price Performance

NASDAQ GRAL opened at $68.56 on Monday. The stock has a market cap of $2.94 billion, a P/E ratio of -6.61 and a beta of 3.22. The company’s 50-day simple moving average is $66.78 and its 200 day simple moving average is $67.33. GRAIL, Inc. has a twelve month low of $29.95 and a twelve month high of $118.84.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.76) by $0.47. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%.The company had revenue of $40.78 million for the quarter, compared to the consensus estimate of $39.16 million. Research analysts anticipate that GRAIL, Inc. will post -10.91 earnings per share for the current year.

Insiders Place Their Bets

In other GRAIL news, insider Andrew John Partridge sold 1,491 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total value of $91,070.28. Following the sale, the insider directly owned 163,738 shares in the company, valued at $10,001,117.04. This represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.83% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on GRAL. The Goldman Sachs Group started coverage on shares of GRAIL in a research note on Friday, June 5th. They issued a “neutral” rating and a $60.00 target price for the company. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Mizuho raised their price objective on GRAIL from $58.00 to $65.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. TD Cowen reissued a “buy” rating on shares of GRAIL in a report on Wednesday, July 15th. Finally, Robert W. Baird set a $70.00 price objective on GRAIL in a research report on Wednesday, May 6th. Four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, GRAIL presently has an average rating of “Hold” and an average price target of $67.78.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.